IL-4 and IL-13 are the major cytokines transforming the tumor-associated macrophages (TAMs) to M2 macrophages that promote cancer progression and treatment resistance, and dupilumab reduces the pro-tumor phenotype of M2 macrophages.4 This evidence concerns the gene IL13 and neoplasm.